CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia

Documents similaires

• Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
  par: Halpern, Anna B., et autres
  Publié: (2019)
• Randomized Phase 1 Study of Sequential (“Primed”) vs. Concurrent Decitabine in Combination with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
  par: Palmieri, Raffaele, et autres
  Publié: (2020)
• Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
  par: Halpern, Anna B., et autres
  Publié: (2020)
• Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
  par: Ciera L. Patzke, et autres
  Publié: (2020-02-01)
• Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
  par: Patzke, Ciera L., et autres
  Publié: (2020)